Published in Food and Drug Law Weekly, April 21st, 2006
GammaCan's scientists, led by professor Yehuda Shoenfeld, MD, have previously shown that plasma-derived IVIg has anti-cancer activity in a number of animal models. More recently, GammaCan has initiated an open label Phase II trial evaluating the anti-cancer properties of plasma-derived IVIg. This trial is expected to conclude later this year and data will be presented after it...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly